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Abstract
Background: The etiology of Parkinson's disease (PD) remains elusive despite identification of
several genetic mutations. It is more likely that multiple factors converge to give rise to PD than
any single cause. Here we report that inflammation can trigger degeneration of dopamine (DA)
neurons in an animal model of Parkinson's disease.
Methods: We examined the effects of inflammation on the progressive 6-OHDA rat model of
Parkinson's disease using immunohistochemistry, multiplex ELISA, and cell counting stereology.
Results:  We show that a non-toxic dose of lipopolysaccharide (LPS) induced secretion of
cytokines and predisposed DA neurons to be more vulnerable to a subsequent low dose of 6-
hydroxydopamine. Alterations in cytokines, prominently an increase in interleukin-1beta (IL-1β),
were identified as being potential mediators of this effect that was associated with activation of
microglia. Administration of an interleukin-1 receptor antagonist resulted in significant reductions
in tumor necrosis factor-α and interferon-γ and attenuated the augmented loss of DA neurons
caused by the LPS-induced sensitization to dopaminergic degeneration.
Conclusion:  These data provide insight into the etiology of PD and support a role for
inflammation as a risk factor for the development of neurodegenerative disease.
Background
Parkinson's disease (PD), to a large extent, is precipitated
by unknown etiological factors. Classically, PD has been
associated with multiple causes ranging from post-
encephalitic PD [1,2] to hereditary PD [3-7] in which
genetic mutations have been associated such as, α-synu-
clein [5], parkin [4], DJ-1 [3], PINK1 [6], and LRRK2 [7].
Genetics, however unlikely acts alone in typical PD. Using
a large cohort of twins Tanner et al. demonstrated no over-
all difference in concordance for PD between monozy-
gotic and dizygotic pairs especially when disease onset
was greater than 50 years [8]. Gaining attention is the con-
cept that idiopathic PD results from combinations of mul-
tiple risk factors that include, age, genetic predisposition,
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environmental toxins, and possibly inflammation [9,10].
The central tenet being that each successive risk factor in
turn engages compensatory mechanisms and eventually
compromises neuronal health beyond recovery [11].
In several epidemiological reports, non-steroidal anti-
inflammatory drugs (NSAIDs) were associated with a
reduced risk of developing PD [12-14]. However, in two
other investigations, although using significantly smaller
sample sizes, no such association was found [15,16].
Chen et al reported that men with elevated plasma levels
of interleukin-6 have an increased risk of developing PD
[17]. Influenza [18,19], traumatic brain injury [20,21]
and allergic rhinitis [22] are speculated as being risk fac-
tors for PD, although these have yet to be verified.
Evidence of an enduring neuroinflammation examined
well into the course of PD has, however, been docu-
mented. In the substantia nigra (SN), inflammation is
represented by activated microglia with increased expres-
sion of major histocompatibility complex-II [23] and ele-
vated levels of pro-inflammatory cytokines including,
tumor necrosis factor-α (TNF-α) [24,25], interleukin-1β
(IL-1β) [25], and interferon-γ [25]. Using magnetic reso-
nance spectroscopy (MRS), we have shown, in the stria-
tum of 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine
(MPTP) treated primates and PD patients, a large increase
in the choline/creatine ratio, possibly reflective of gliosis
or macrophage activity [26]. In addition, intercellular
adhesion molecule-1 (ICAM-1, CD54) is highly expressed
on astrocytes in the SN of PD patients and accordingly its
receptor, lymphocyte function-associated antigen-1 (LFA-
1) was observed on microglia and infiltrating leukocytes
[27], indicating a role for immune regulation outside of
the CNS.
Several investigators suggest that treatments aimed at con-
trolling inflammation may be beneficial in curbing cell
loss associated with PD progression. For example,
cyclooxygenase-2 inhibition has been shown to reduce
cell loss in rodent [28] and non-human primate models
of PD (Sánchez Pernaute R, Brownell AL, Viñuela A, Zhu
A, Koprich JB, McDowell J, Pagel O'Malley J, Wang X, Yu
M, Isacson O, submitted). In addition, minocycline [29],
dexamethasone [30], blocking tumor necrosis factor
alpha (TNF-α) [31] and nNOS (neuronal nitric oxide syn-
thase) inhibition [32] have all reduced inflammation and
demonstrated efficacy in animal models of PD. While
these data suggest that inflammation is involved in PD
progression, less is known about its role in disease onset.
The intra-striatal 6-OHDA rat model of PD produces an
irreversible and progressive loss in DA neurons of the SN
[33]. Interestingly this lesion results in an inflammatory
response [34] that can only be controlled approximately
12 days after lesion onset [28], making this an ideal ani-
mal model for gaining insights into inflammation and PD
pathogenesis. With some modifications, we utilized this
animal model to examine whether neuroinflammation
contributes to the onset of PD. To this end we induced a
non-toxic inflammation in the SN using a low dose of
lipopolysaccharide (LPS) followed by a low dose of 6-
OHDA to simulate the early stages of PD. We report that
preexisting inflammation increases the magnitude of cell
loss produced by 6-OHDA. Furthermore, we identified IL-
1β as a potential mediator of this effect and were able to
reverse the cell loss in our paradigm through administra-
tion of an interleukin-1 receptor antagonist.
Methods
Animals
Female Sprague-Dawley rats weighing ~280 g (Charles
River Laboratories) were used in all animal experiments.
All rat studies were approved by the McLean Hospital
Institutional Animal Care and Use Committee.
Stereotaxic surgery
All stereotaxic coordinates were derived from the Rats
Atlas of Paxinos and Watson [35]. For each surgery ani-
mals were deeply anesthetized with ketamine and xyla-
zine (60 mg/kg and 3 mg/kg respectively, i.m.). Substantia
nigra LPS injection. Animals received a single 2.0 μl stereo-
taxic injection of either lipopolysaccharide (0.09 μg LPS,
serotype 026:B6, Sigma-Aldrich) or saline and delivered at
a rate of 0.5 μl/min using microinfusion pumps (Stoelting
Co, Wood Dale, IL) with a 5 min wait time after injection.
SN injection coordinates were as follows: AP -4.8, ML -2.0,
DV -7.3, and tooth bar set at -3.3. 6-OHDA intra-striatal
injection. Animals received a single 3.5 μl stereotaxic injec-
tion of 6-OHDA (total dose = 5.0 or 22.5 μg 6-OHDA pre-
pared as free base, Sigma-Aldrich) delivered at a rate of 0.5
μl/min and a 5 min wait time after injection. Striatum
injection coordinates were as follows: AP +0.2, ML -3.0,
DV -5.0, and tooth bar set at -3.3. The lesion was allowed
to progress for 3 weeks after which animals were sacrificed
for post mortem analyses.
Interleukin-1ra (IL-1ra) administration
IL-1ra (Anakinra) (Amgen, Thousand Oaks, CA) was pur-
chased through McLean Hospital Pharmacy and prepared
as a 100 mg/mL solution. Osmotic pumps (model 2ML1,
Alzet, Cupertino, CA) were filled with either IL-1ra (to
deliver: 3.64 mg/kg/hr IL-1ra, s.c.) or vehicle and
implanted subcutaneously under ketamine and xylazine
anesthesia (60 mg/kg and 3 mg/kg respectively, i.m.).
Pumps were replaced weekly until completion of the
study. IL-1ra has previously been shown to cross the
blood brain barrier and achieve therapeutic concentra-
tions [36,37].Journal of Neuroinflammation 2008, 5:8 http://www.jneuroinflammation.com/content/5/1/8
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Perfusions and tissue handling
Animals were deeply anesthetized with an i.p. injection of
sodium pentobarbital and were sacrificed by exsanguina-
tion with the aid of ice-cold saline perfusion. For immu-
nohistochemistry, the brains were then fixed with a 4%
paraformaldehyde solution. The brains were then
removed from the skull and placed in fresh 4% parafor-
maldehyde solution for 1 h, and equilibrated through
20% and 30% sucrose solutions and refrigerated until cut-
ting for immunohistochemistry. For ELISA, brains were
rapidly removed after saline perfusion and sliced coro-
nally using a tissue chopper set to 1 mm (Campden
Instruments Ltd., Lafayette, IN). On an inverted glass Petri
dish over ice, regions of interest (striatum and substantia
nigra region) were dissected from the individual 1 mm tis-
sue slices, frozen on dry ice, and stored at -80°C.
Immunohistochemistry
Brains were cut frozen in the coronal plane at a thickness
of 40 μm on a sliding microtome and six series of sections
were stored in cryoprotectant. One-sixth series of sections
were processed for visualization of tyrosine hydroxylase
(TH) or CD11b via the biotin-labeled antibody proce-
dure. Briefly, following several washes in a PBS solution
containing 0.01% Triton ×-100 (PBS-T), endogenous per-
oxidase was quenched in a 3% hydrogen peroxide solu-
tion and background staining was then inhibited in a 5%
normal goat serum solution. Tissue was then incubated
with rabbit anti-TH antibody overnight (1:1000, Pel-
Freez, Rogers, AR) or mouse anti-CDllb (1:100, Serotec,
UK). After three washes in PBS-T, sections were sequen-
tially incubated in biotinylated goat antibodies IgG
(1:500; Vector, Burlingame, CA) for 1 h and the Elite avi-
din-biotin complex (ABC Kits; Vector, Burlingame, CA)
for 1 h separated by three washes in PBS. TH and CD11b
immuno staining was visualized following a reaction with
3,3-diaminobenzidine (Vector). Sections were then
mounted on glass slides, allowed to dry, dipped into
dH20, dehydrated through graded alcohol (70%, 95%,
100%), cleared in xylenes, and coverslipped with DPX
mounting medium.
Multiplex ELISA
Tissue samples were collected and suspended in lysis
buffer (TPER, Peirce, Rockford, IL). In addition, phos-
phatase inhibitors I-II (1:100) and protease inhibitors
(1:100) were added fresh prior to cell lysis (Sigma-
Aldrich, P2850, P5276, and P8340 respectively). Follow-
ing cell lysis, the homogenate was centrifuged, a portion
of the supernatant was reserved for protein determination
(BCA Assay, Pierce, Rockford, IL) and the remaining was
stored at -20°C. Samples were analyzed for the simultane-
ous detection of IL-1β, IL-2, IL-4, IL-6, IL-10, IFNγ, TNF-α,
MCP-1, and Fractalkine using a multiplex ELISA based
format and performed in duplicate. Testing was per-
formed independently through the Searchlight Testing
Service (Pierce, Thermo Fisher Scientific, Woburn, MA).
Cell counting
Estimates of TH-positive neuronal number within the
substantia nigra (SN) were performed using Stereo Inves-
tigator software (MBF Bioscience, Williston, VT) and ster-
eologic principles. Six sections, each separated by 240 μm
from the anterior to the posterior SN, were used for count-
ing of each case. Stereology was performed using a Zeiss
Axiovert microscope (Zeiss, Thornwood, NY) coupled to
an Optronics Microfire digital camera (Goleta, CA) for vis-
ualization of tissue sections. The total number of TH-pos-
itive neurons was estimated from coded slides using the
optical fractionator method. For each tissue section ana-
lyzed, section thickness was assessed empirically and
guard zones of 2 μm thickness were used at the top and
bottom of each section. The SN was outlined under low
magnification (2.5×) and approximately 54% of the out-
lined region was analyzed using a systematic random
sampling design generated with the following stereologic
parameters: grid size, 170 × 170 μm; counting frame size,
125 × 125 μm; and dissector height, 18 μm. Neurons were
counted under 40× magnification. The coefficients of
error (CE) were calculated according to the procedure of
West and colleagues, values <0.10 were accepted [38].
Statistical analyses
1-way ANOVA was used to compare more than 2 groups
on the same dependent measure and post-hoc analysis
(Holm-Sidak) was conducted to reveal simple effects. Stu-
dent t-tests were used to compare two groups on a single
dependent measure. All analyses were conducted using
Sigma Stat v. 3.0 (San Jose, CA). All tests were considered
significant at p < 0.05.
Results
Preexisting neuroinflammation contributes to 6-OHDA 
induced dopamine neuron loss in the substantia nigra
Rats received a single intra-nigral injection of LPS (0.09
μg) either prior to or following an intra-striatal injection
of 6-OHDA. Each condition was allowed 21 days post 6-
OHDA administrations for consistent comparison of
lesion severity (Fig. 1a–b). This experiment was designed
to test the hypothesis of whether direct inflammation in
the midbrain contributes to the onset and/or the progres-
sion of SN DA neuron cell loss. One-way ANOVA revealed
an overall main effect indicating significant differences in
cell counts across all treatment conditions [F(5,33) =
42.11, p < 0.001]. More specifically through post-hoc
analysis, LPS injection into the SN followed by saline
injection into the striatum produced no significant TH-ir
cell loss in the SN compared to saline injections alone (t
= 1.30, NS) (Fig. 2b–c), indicating that the dose of LPS
chosen did not produce cell loss on its own. This dose ofJournal of Neuroinflammation 2008, 5:8 http://www.jneuroinflammation.com/content/5/1/8
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LPS was selected based on a dose response study deter-
mining the presence of an inflammatory response without
overt TH-ir cell loss (unpublished data). Animals receiv-
ing an injection of saline into the SN followed by intra-
striatal injection of 6-OHDA (5.0 μg) experienced a 52%
loss of TH-ir cells in the SN (t = 11.62, p < 0.001) com-
pared to control (Fig. 2b vs. 2d). Prior neuroinflammation
generated by LPS followed by intra-striatal injection of 6-
OHDA produced a greater TH-ir cell loss (72%) compared
to intra-nigral injection of saline followed by intra-striatal
injection of 6-OHDA (t = 3.95, p < 0.05) (Fig. 2d–e). In
contrast, LPS injection into the SN during an ongoing 6-
OHDA induced degeneration produced no further cell
loss as compared to 6-OHDA in combination with saline
(t = 0.36, NS) (Fig. 2d vs. 2f).
To provide context to the combined lesion effect of LPS
followed by 6-OHDA (5.0 μg) we also included a group
that received a higher dose of 6-OHDA (22.5 μg) alone.
The amount of cell loss produced by this dose (66%) was
not significantly different from animals receiving LPS fol-
lowed by 5.0 μg of 6-OHDA (t = 0.84, NS) (Fig. 2g vs. 2e).
Microglia activation in the ventral midbrain following 
administration of LPS and 6-OHDA
In the experiment described above, LPS administration
increased the amount of cell loss produced by 6-OHDA.
We next wanted to understand how LPS produced
increased vulnerability of SN DA neurons in this para-
digm. In these experiments, animals were killed 12 days
following either injection of LPS (intra-nigral) or 6-
OHDA (intra-striatal) (Fig. 1c–d). We next determined
the degree of microglia activation using CD11b as a
marker. Greater staining intensity and a shift in cell mor-
phology towards full activation (resting microglia appear
as having smaller soma with fine processes, compared to
activated microglia having larger soma and short thicker
processes) were used as the basis of comparison [39]. Ani-
Experimental timelines Figure 1
Experimental timelines. Each timeline represents in vivo experimental procedures and postmortem analyses conducted. 
Number of animals in each group: (A) n = 6, (B) n = 6, (C) n = 7, (D) n = 7, (E) n = 5, (F) n = 8. LPS, lipopolysaccharide; 6-
OHDA, 6-hydroxydopamine, SAL, saline; IL-1ra, interluekin-1 receptor antagonist; veh, vehicle; SN, substantia nigra, Str, stria-
tum.Journal of Neuroinflammation 2008, 5:8 http://www.jneuroinflammation.com/content/5/1/8
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(A) Tyrosine hydroxylase positive (TH+) cell counts in the substantia nigra (SN) Figure 2
(A) Tyrosine hydroxylase positive (TH+) cell counts in the substantia nigra (SN). (B) Animals received, into the SN, saline (SAL) 
and 12 days later received an intra-striatal injection of SAL. (C) Animals received lipopolysaccharide (LPS) into the SN and 12 
days later received an intra-striatal injection of SAL. (D) Animals received SAL into the SN and 12 days later received an intra-
striatal injection of 6-OHDA (5.0 μg). (E) Animals received LPS into the SN and 12 days later received an intra-striatal injection 
of 6-OHDA (5.0 μg). (F) Animals received an intra-striatal injection of 6-OHDA (5.0 μg) and 12 days later received LPS into the 
SN. (G) Animals received an intra-striatal injection of 6-OHDA-h (high) (22.5 μg). Letters inside bars of panel A represent 
respective images in panels below. 21 days was allowed following 6-OHDA injection in all conditions. There was an overall 
main effect across groups (ANOVA, p < 0.001). LPS injection into the SN was non-toxic to TH+ neurons (B vs. C, NS). LPS 
injection prior to 6-OHDA administration increased the amount of TH+ cell loss compared to SAL prior to 6-OHDA (D vs. E, 
*p < 0.05, post-hoc Holm-Sidak). Intra-striatal injection of 6-OHDA followed by injection of LPS in the SN produced no 
greater cell loss (D vs. F, NS). The high dose of 6-OHDA produced cell loss that was not significantly different from a low dose 
of 6-OHDA with prior exposure to LPS (E vs. G, NS), however the high dose of 6-OHDA was significantly greater than other 
conditions receiving the lower dose of 6-OHDA (G vs. D and F, # p < 0.05, post-hoc Holm-Sidak). 1st, first injection; 2nd, second 
injection; SNpc, pars compacta; SNpr, pars reticulata; VTA, ventral tegmental area; CP, cerebral peduncle; scale bar, 1.0 mm; 
magnification, 2.5×. Error bars, ± SEM; n = 6 per condition.Journal of Neuroinflammation 2008, 5:8 http://www.jneuroinflammation.com/content/5/1/8
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mals that received LPS or 6-OHDA had greater staining
intensity of CD11b and a more advanced activated mor-
phology compared to their respective contralateral sides
(Fig. 3a–d). Furthermore, LPS induced changes appeared
to be greater than that produced by 6-OHDA (Fig. 3a vs.
3c). These data served to indicate that the dose of LPS
injected into the SN produced inflammation in the
absence of overt TH+ cell loss (Fig. 2c).
Cytokine and chemokine alterations following LPS 
injection into the substantia nigra
We next screened a panel of cytokines and chemokines in
order to obtain a more in depth analysis of the increased
susceptibility of DA neurons produced by the bacterial
endotoxin, LPS. A new set of animals was injected, as
before, with LPS, 6-OHDA, or saline as respective controls
(Fig. 1d–e). A panel of cytokines and chemokines was
selected and quantified in the SN and striatum of each
animal using a multiplex ELISA format. Table 1 shows the
values obtained from SN tissue alone following either
LPS/saline or 6-OHDA/saline injections. We found that
twelve days following LPS injection into the SN there was
a significant increase in SN IL-1β [t(11) = 6.25, p < 0.001]
and MCP-1 [t(11) = 2.57, p < 0.05) and a significant
decrease in IL-4 [t(11) = 3.15, p < 0.01] compared to
saline controls. No significant changes were seen in the
SN following a 6-OHDA injection (Table 1). We also
quantified levels in the striatum following LPS/saline or 6-
OHDA/saline injections and found no significant differ-
ences in protein levels in either condition (Table 2).
Administration of IL-1ra produces changes in ventral 
midbrain cytokine content and reduces the cell loss 
produced by LPS and 6-OHDA
From the cytokine/chemokine profile generated in the
previous experiment we selected IL-1β as being poten-
tially involved with the increased 6-OHDA degeneration
induced by prior LPS. To test this hypothesis we first
administered an IL-1ra or vehicle to the periphery via sub-
cutaneous osmotic pumps (3.64 mg/kg/hr IL-1ra, s.c.) to
animals 9 days following a LPS injection into the SN. On
the twelfth day animals were sacrificed and processed for
ventral midbrain cytokine/chemokine levels (Fig. 1e). We
found that LPS exposed animals treated with IL-1ra had a
Representative coronal sections of microglia in the ventral midbrain at the level of the substantia nigra (SN) visualized by  CD11b-immunoreactivity (-ir) Figure 3
Representative coronal sections of microglia in the ventral midbrain at the level of the substantia nigra (SN) visualized by 
CD11b-immunoreactivity (-ir). (A) activated microglia in the SN of a rat injected in the SN with LPS 12 days prior and (B) the 
contralateral side. (C) low level of microglia activation 12 days following an intra-striatal injection of 6-OHDA (5.0 μg) and (D) 
the contralateral side showing resting microglia. Insets are 20× images taken from the area outlined in lower magnification pic-
tures. Scale bar of inset, 100 μm; scale bar of low magnification images (2.5×), 1.0 mm).Journal of Neuroinflammation 2008, 5:8 http://www.jneuroinflammation.com/content/5/1/8
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significant decrease in TNF-α [t(8) = 3.28, p < 0.01] and
IFN-γ [t(8) = 2.47, p < 0.05] compared to LPS exposed ani-
mals receiving vehicle (Table 3). No significant changes in
IL-1β were observed, however changes in TNF-α and IFN-
γ are indicative of alterations in IL-1 signaling [40]. These
data demonstrated that peripheral IL-1ra administration
can exert its effects across the blood brain barrier.
We next conducted a study to test whether IL-1ra admin-
istration could prevent the synergistic increase in TH-ir
cell loss produced by LPS and 6-OHDA. All animals
received an intra-nigral injection of LPS, followed by
either IL-1ra or vehicle from day 9 until sacrifice, and
finally, all animals received an intra-striatal injection of 6-
OHDA (Fig. 1f). Each animal receiving IL-1ra had signifi-
cantly greater IL-1ra serum protein levels, measured by
ELISA, at the end of the study (data not shown). Postmor-
tem analysis revealed that significantly more TH-ir cells
remained in the SN of animals that received IL-1ra com-
pared to vehicle treated controls [t(11) = 2.54, p < 0.05]
(Fig. 4), indicating that blocking of IL-1 signaling signifi-
cantly reduces the degree of degeneration produced by the
combination of LPS and 6-OHDA.
Discussion
The present study demonstrates that preexisting inflam-
mation in the brain, produced locally by LPS, potentiates
the amount of DA neuron loss generated in the intra-stri-
atal 6-OHDA rat model of PD. Furthermore, we report
that LPS elevates IL-1β levels in the midbrain and is
important in creating this increase in vulnerability. This
was evidenced by attenuated cell loss after administration
of an IL-1 receptor antagonist. These data support a role
for inflammation as a potential component in the devel-
opment of idiopathic PD.
LPS is derived from gram-negative endotoxin bacterium
that acts through a membrane bound receptor complex
Table 1: Substantia nigra tissue ELISA. Levels of cytokines/chemokines in the substantia nigra 12 days following an intra-nigra injection 
of LPS/saline or intra-striatal injection of 6-OHDA/saline.
Cytokine or Chemokine Substantia nigra protein levels (pg/mg) ± SEM
Substantia nigra Striatum
SAL LPS SAL 6OHDA
IL-1β 7.17 ± 0.64 13.54 ± 0.69** 7.58 ± 0.64 6.92 ± 0.71
MCP-1 5.12 ± 0.71 8.14 ± 0.64* 3.96 ± 0.25 5.07 ± 0.42
IL-4 0.46 ± 0.07 0.26 ± 0.01* 0.63 ± 0.16 0.45 ± 0.03
IFN-γ 9.88 ± 1.48 8.02 ± 0.49 13.00 ± 1.32 10.11 ± 1.13
IL-10 1.73 ± 0.05 1.46 ± 0.17 1.74 ± 0.13 1.61 ± 0.10
IL-2 20.58 ± 0.98 23.17 ± 4.33 24.05 ± 1.71 22.84 ± 1.29
TNF-α 5.66 ± 0.20 6.82 ± 0.18 6.92 ± 0.80 6.47 ± 0.43
Fractalkine 20.67 ± 2.07 18.40 ± 1.20 19.91 ± 1.04 20.73 ± 0.55
IL-6 5.95 ± 0.60 5.32 ± 0.37 5.65 ± 0.49 5.97 ± 0.40
*p < 0.05; **p < 0.01; SAL, saline; LPS, lipopolysaccharide
Table 2: Striatum tissue ELISA. Levels of cytokines/chemokines in the striatum12 days following an intra-nigral injection of LPS/saline 
or intra-striatal injection of 6-OHDA/saline.
Cytokine or Chemokine Striatum protein levels (pg/mg) ± SEM
Substantia nigra Striatum
SAL LPS SAL 6OHDA
IL-1β 2.29 ± 0.45 2.41 ± 0.26 3.03 ± 0.48 2.96 ± 0.35
MCP-1 0.76 ± 0.06 0.79 ± 0.06 6.20 ± 1.24 4.36 ± 1.76
IL-4 0.20 ± 0.03 0.25 ± 0.05 0.13 ± 0.02 0.17 ± 0.04
IFN-γ 3.58 ± 0.46 3.76 ± 0.39 3.95 ± 0.41 3.89 ± 0.26
IL-10 0.61 ± 0.07 0.57 ± 0.04 0.69 ± 0.04 0.68 ± 0.05
IL-2 10.02 ± 0.70 10.01 ± 0.79 10.08 ± 0.36 10.99 ± 0.92
TNF-α 2.50 ± 0.20 2.44 ± 0.18 2.43 ± 0.27 2.56 ± 0.14
Fractalkine 14.33 ± 0.80 13.97 ± 0.21 15.54 ± 0.71 16.59 ± 0.86
IL-6 2.81 ± 0.27 3.19 ± 0.24 3.14 ± 0.46 2.78 ± 0.29
SAL, saline; LPS, lipopolysaccharideJournal of Neuroinflammation 2008, 5:8 http://www.jneuroinflammation.com/content/5/1/8
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found on the surface of microglia [41]. Its primary action
initiates nuclear translocation of transcription factor
nuclear factor κB (NF-κB) and the upregulation of pro-
inflammatory gene expression [42]. Following injection
into the midbrain, LPS has been shown to activate micro-
glia [43], increase pro-inflammatory cytokine levels [44],
and directly result in death of DA neurons [45-50] that is
dependent on tyrosine hydroxylase activity [47], while
sparing other phenotypes (Gamma-aminobutyric acid
and serotonin neurons) [48]. Direct injection of LPS into
other brain areas (hippocampus and cortex) also pro-
duces no overt cell loss [51], indicating that DA neurons
possess a relative vulnerability to the direct effects of
inflammation.
In the current study we found that a non-DA-toxic dose of
LPS (0.09 μg) delivered to the SN produces activation of
microglia and alterations in select cytokines as measured
twelve days later. In the SN, the pro-inflammatory
cytokine IL-1β and the chemokine, MCP-1 were signifi-
cantly elevated, while there was a significant decrease in
the anti-inflammatory cytokine, IL-4. IL-1β is a potent
pro-inflammatory cytokine that acts through IL-1 recep-
tors found on numerous cell types including neurons and
microglia. IL-1 signaling leads to NF-κB mediated expres-
sion of pro-inflammatory cytokines, thereby perpetuating
the cycle of inflammation initiated by LPS. In PD patients,
IL-1β is elevated in CSF [52], striatum [53], and SN [25].
Genetic studies have revealed that the T allele in the regu-
latory region of the IL-1β gene (-511) is elevated in PD
patients and may be responsible for increased IL-1β
expression [54,55]. In relation to the current study, over-
expresssion of IL-1β in these patients may have lead to
increased DA neuron vulnerability to exogenous toxins
and an increased risk for PD onset. In contrast, it has been
shown that PD patients of a Japanese cohort with higher
expression of IL-β had a later age of disease onset com-
pared to lower expressing patients [56]. These data indi-
cate that IL-1β may be important in PD onset and that
more research needs to be done to determine its exact role.
In rat, it has been shown that direct delivery of IL-1β to the
midbrain produces DA neuron degeneration in the SN
[57]. The combination of independently non-toxic doses
of quinolinic acid and IL-1β has been shown to synergis-
tically produce pyramidal cell loss in the hippocampus
[58]. Interleukin-1β is therefore a potent regulator of
Table 3: Cytokine and chemokine protein levels (pg/mg) ± SEM 
in substantia nigra of animals treated with IL-1ra or vehicle. All 
animals received an intra-nigra injection of LPS 9 days prior to 
drug treatment. IL-1ra treatment lasted for 3 days.
Cytokine/Chemokine Vehicle IL-1ra
IL-1β 9.32 ± 1.38 9.61 ± 2.48
MCP-1 12.48 ± 2.58 10.56 ± 1.71
IFN-γ 2.42 ± 0.38 1.32 ± 0.23*
IL-10 0.22 ± 0.03 0.15 ± 0.02
IL-1α 1.27 ± 0.04 1.03 ± 0.17
TNF-α 2.35 ± 0.29 1.16 ± 0.22*
Fractalkine 14.64 ± 1.37 15.21 ± 1.45
IL-6 13.18 ± 2.71 9.13 ± 1.25
*p < 0.05; IL-4 was below detectable limits.
Interleukin-1 receptor antagonist (IL-1ra) reduces the amount of tyrosine hydroxylase-immunoreactive (TH-ir) cell loss associ- ated with LPS and 6-OHDA (t-test, *p < 0.05) Figure 4
Interleukin-1 receptor antagonist (IL-1ra) reduces the amount of tyrosine hydroxylase-immunoreactive (TH-ir) cell loss associ-
ated with LPS and 6-OHDA (t-test, *p < 0.05). Each animal received LPS into the substantia nigra (SN), 9 days later started on 
either IL-1ra or vehicle (Veh) which continued through the experiment, and all animals then received an intra-striatal injection 
of 6-OHDA (5.0 μg) and were allowed 21 days until post-mortem analyses. Magnification, 2.5×; scale bar, 1.0 mm. Error bars, 
± SEM; n = 8 per condition.Journal of Neuroinflammation 2008, 5:8 http://www.jneuroinflammation.com/content/5/1/8
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inflammation and has been shown to be associated with
neurodegenerative disease.
A sustained inflammatory response to our single LPS
injection is evidenced by increases in MCP-1 and a stable
state of microglia activation. MCP-1 is expressed and
released by DA neurons when an activating stimulus con-
tinues to be present [39] and through interaction with its
microglial receptor, chemokine receptor 2 (CCR2)
[59,60], is able to direct the chemotaxis of microglia
towards neurons to promote cell-cell contact [39]. Persist-
ent levels of IL-1β, MCP-1 and activated microglia in our
paradigm (at least 12 days following LPS injection) may,
at least in part, be responsible for the increase in SN DA
neuron susceptibility to 6-OHDA we observed in the
present study.
To provide context to our combined insult paradigm, in
terms of 6-OHDA lesion severity, we also included a
group that received a higher dose of 6-OHDA alone. We
found that LPS delivered to the SN prior to the intra-stri-
atal injection of 6-OHDA (5.0 μg) produced the same
degree of TH+ cell loss in the SN as a striatal injection of
22.5 μg of 6-OHDA (p > 0.05, NS). These data indicate
that preexisting neuroinflammation potentiates the
effects of a 5.0 μg 6-OHDA to that of a 22.5 μg dose.
Through systemic administration of IL-1ra we were able to
reverse the vulnerability produced by LPS and therefore
eliminate its contribution to 6-OHDA induced DA cell
death. IL-1ra administered in the periphery has previously
been shown to cross the blood brain barrier [36,37]. In
support of this we show that IL-1ra administration
reduces levels of the pro-inflammatory cytokines IFN-γ
and TNF-α in the SN following three days of exposure.
Cross regulation between IL-1β, TNF-α, and IFN-γ is not
surprising considering the substantial overlap in intra-cel-
lular/nuclear signaling they possess [61]. Sites of overlap
include, phospholipid hydrolysis and protein tyrosine
kinase phosphorylation in the cell and shared nuclear
binding motifs, κB and NF-IL6 [62-65]. All three
cytokines share the transcription factor Nf-κB, a key regu-
lator of pro-inflammatory cytokine expression [66-68]. IL-
1ra administration therefore may not have only attenu-
ated cell loss through blockade of IL-1 signaling per se,
but also these data suggest that regulation of other
cytokines (TNF-α and IFN-γ) likely also contributed.
Importantly, both IFN-γ and TNF-α are found to be
increased in the human PD brain [69] and can be toxic to
DA neurons when injected into the rat brain [57]. Inter-
feron-γ was recently shown to be elevated in PD serum
[70] and was implicated in MPTP induced DA neuron
degeneration in mice [70]. In several reports, TNF-α sign-
aling has been shown to be involved in the destruction of
SN DA neurons in animal models of PD [31,70-73]. This
report and others further point to the adverse role
cytokines can play in DA neuron survival, while in con-
trast providing potential therapeutic targets.
IL-1ra delivery to the CNS has also been used successfully
in a rodent stroke model where infarct size was signifi-
cantly reduced [74]. In humans, IL-1ra administration
(Anakinra, s.c., Amgen) is well tolerated and is approved
for use in patients with rheumatoid arthritis. Further
research into IL-1ra as a potential therapy in neurodegen-
erative disease is therefore warranted.
Inflammation produced by a single injection of a large
dose of LPS into the periphery has recently been shown to
produce inflammation in the brain and resulted in signif-
icant DA neuron loss in the SN at 7 months and progres-
sively more so at 10 months in the absence of a second
insult [75]. These data along with those reported here
indicate that inflammation produced both locally and
systemically have the potential to not only create DA neu-
ron vulnerability, but also frank cell loss.
Our data fit with the threshold or "multiple hit" hypothe-
sis of neurodegenerative disease and sporadic PD [9,10].
According to these hypotheses several risk factors of PD,
including genetic predisposition, toxin exposure, aging,
and other as of yet unknown factors interact to facilitate
DA cell loss past the threshold of PD onset. Several reports
support this hypothesis and reveal that disparate chal-
lenges drain multiple compensatory mechanisms leading
to greater cell loss [11]. For example, we have previously
shown that the combination of two otherwise non-toxic
doses of NMDA and 3-nitropropionic acid (3-NP) results
in striatal cell death [76]. Prenatal exposure to LPS pro-
duces increased DA cell loss following adult exposure to
6-OHDA [77]. Peng et al. recently showed that neonatal
exposure to iron produces a greater loss of SN DA neurons
combined with paraquat administration in adulthood (24
months old) [78]. The combination of genetic and envi-
ronmental insults has also produced Parkinson's like
pathology. It was found that a double-mutant human
alpha-synuclein overexpressing mouse exposed to pesti-
cides (maneb and paraquat) showed SN DA cell loss in
greater magnitude than either single insult alone [79].
The present study suggests that preexisting neuroinflam-
mation is a risk factor for the development of PD. This is
supported clinically, by the finding that the relative risk of
being diagnosed with PD is reduced by the use of NSIADs
[12-14]. Interestingly, a clinical phenotype of PD emerged
following the outbreak of the Spanish flu in 1918 [80]
and while viral RNA is reported absent from brains of the
deceased [81], it is conceivable that the massive immune
response or "cytokine storm" [82] created by the virus ini-
tiated inflammation in the CNS. This has been shown inJournal of Neuroinflammation 2008, 5:8 http://www.jneuroinflammation.com/content/5/1/8
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an experimental sepsis model, where LPS delivered sys-
temically to mice leads to neuroinflammation and the
eventual death of SN DA neurons with an apparent spar-
ing of neighboring DA ventral tegmental neurons [75].
Conclusion
In conclusion, these experiments demonstrate that mild
inflammation caused by a bacterial endotoxin can
increase the vulnerability of midbrain DA neurons to PD-
like degeneration in vivo, and identify the specific changes
in cytokine brain tissue levels associated with the
increased risk of degeneration. Based on the tissue
cytokine profile showing elevated IL-1β, systemic therapy
using an IL-1 receptor antagonist provides direct evidence
in animal models that the inflammation induced neuro-
nal vulnerability can be counteracted. These data give new
insights into how low-grade inflammation may trigger the
onset of PD and other neurodegenerative diseases and the
specific therapeutic avenues to limit such pathogenesis.
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